Israel, another example, has led the way with ground-breaking research into cannabis cultivation. The country recently recognized medical marijuana as an official part of the nation’s branch of agriculture. Israel is already one of the world’s leading exporters of medical-grade cannabis. Recognizing marijuana cultivation as an official branch of the country’s agriculture will open up even more funds to support Israeli cannabis farmers.
The U.S. hemp-derived CBD market alone is projected to reach $450 million by 2020, and China's cannabis market could grow to 100 billion yuan by 2022 (approximately $14.5 billion). Hemp is already interwoven into the futures of the automotive, construction, energy, environmental mediation and technology industries. Once fully utilized and legal, this plant could impact the global economic positionings of North America, China and Africa.
What makes CBD so appealing is that it’s non-intoxicating, so it won’t get you high, though it “is technically psychoactive, because it can influence things like anxiety,” Jikomes said. Although much of the marketing blitz around CBD centers on the fact that you can take it without getting stoned, there isn’t much research looking at the effects of CBD when used in isolation, with a couple of exceptions. One is the use of CBD to treat seizures: CBD is the active ingredient in the only cannabis product that the Food and Drug Administration has signed off on — a drug called Epidiolex, which is approved for treating two rare forms of epilepsy. Animal models and a few human studies suggest that CBD can help with anxiety, but those are the only conditions with much research on CBD in isolation.
PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”
In 2014, I founded New Frontier Data, an analytics and business intelligence reporting group dedicated to the global cannabis industry, after more than 20 years in finance, industry analytics, intelligence reporting and emerging markets. As such, I have had the privilege of following hemp’s emergence and evolution. Half a decade later, this robust, environmentally friendly, low -cost-to-produce plant has become one of the most diversely applied and globally significant natural resources in the world. Here is a look at its applications across several mature industries:
Hemp, or industrial hemp (from Old English hænep), typically found in the northern hemisphere, is a variety of the Cannabis sativa plant species that is grown specifically for the industrial uses of its derived products. It is one of the fastest growing plants and was one of the first plants to be spun into usable fiber 10,000 years ago. It can be refined into a variety of commercial items including paper, textiles, clothing, biodegradable plastics, paint, insulation, biofuel, food, and animal feed.
Synthetic cannabis is illegal in New Zealand. It is designed to imitate the effects of cannabis and is usually dried plant material sprayed with chemicals known as synthetic cannabinoids. It is also available in liquid form. Little is known about the chemicals used in synthetic cannabis and the effects can be unpredictable, especially when mixed with other substances.
Industrial hemp is from the plant species Cannabis sativa and has been used worldwide to produce a variety of industrial and consumer products. Hemp is a source of fiber and oilseed grown in more than 30 nations. In the United States production is controlled under drug enforcement laws. To produce industrial hemp in the United States the grower must obtain a permit from the Drug Enforcement Agency (DEA).
Cannabis , also known as marijuana, originated in Central Asia but is grown worldwide today. In the United States, it is a controlled substance and is classified as a Schedule I agent (a drug with a high potential for abuse, and no currently accepted medical use). The Cannabis plant produces a resin containing psychoactive compounds called cannabinoids, in addition to other compounds found in plants, such as terpenes and flavonoids. The highest concentration of cannabinoids is found in the female flowers of the plant. Clinical trials conducted on medicinal Cannabis are limited. The U.S. Food and Drug Administration (FDA) has not approved the use of Cannabis as a treatment for any medical condition. To conduct clinical drug research with Cannabis in the United States, researchers must file an Investigational New Drug (IND) application with the FDA, obtain a Schedule I license from the U.S. Drug Enforcement Administration, and obtain approval from the National Institute on Drug Abuse.
It is often claimed by growers and breeders of herbal cannabis that advances in breeding and cultivation techniques have increased the potency of cannabis since the late 1960s and early '70s when THC was first discovered and understood. However, potent seedless cannabis such as "Thai sticks" were already available at that time. Sinsemilla (Spanish for "without seed") is the dried, seedless inflorescences of female cannabis plants. Because THC production drops off once pollination occurs, the male plants (which produce little THC themselves) are eliminated before they shed pollen to prevent pollination. Advanced cultivation techniques such as hydroponics, cloning, high-intensity artificial lighting, and the sea of green method are frequently employed as a response (in part) to prohibition enforcement efforts that make outdoor cultivation more risky. It is often cited that the average levels of THC in cannabis sold in the United States rose dramatically between the 1970s and 2000, but such statements are likely skewed because undue weight is given to much more expensive and potent, but less prevalent samples.
It was the seizures that tipped Penny off that something wasn’t right with Harper after she and her husband Dustin brought her home from the hospital as a newborn. Several months later, having tried a battery of epilepsy medications and still without a diagnosis, Penny and Dustin flew to Boston with Harper to see an expert in infant seizures. It was there they first heard of CDKL5. “This is the point where life changed significantly,” Penny said, “because now we had this diagnosis. You know, this abnormality in our family that we cannot fix.”
The vegetable oils have been classified by “iodine value” as drying (120–200), semi-drying (100–120), and non-drying (80–100), which is determined by the degree of saturation of the fatty acids present (Raie et al. 1995). Good coating materials prepared from vegetable oil depend on the nature and number of double bonds present in the fatty acids. Linseed oil, a drying oil, has a very high percentage of linolenic acid. Hempseed oil has been classified as a semi-drying oil, like soybean oil, and is therefore more suited to edible than industrial oil purposes. Nevertheless hemp oil has found applications in the past in paints, varnishes, sealants, lubricants for machinery, and printing inks. However, such industrial end uses are not presently feasible as the oil is considered too expensive (de Guzman 2001). Larger production volumes and lower prices may be possible, in which case hemp oil may find industrial uses similar to those of linseed (flax), soybean, and sunflower oils, which are presently used in paints, inks, solvents, binders, and in polymer plastics. Hemp shows a remarkable range of variation in oil constituents, and selection for oilseed cultivars with high content of valued industrial constituents is in progress.
Hemp, grown under license mostly in Canada, is the most publicized “new” crop in North America. Until very recently the prohibition against drug forms of the plant prevented consideration of cultivation of fiber and oilseed cultivars in Canada. However, in the last 10 years three key developments occurred: (1) much-publicized recent advances in the legal cultivation of hemp in western Europe, especially for new value-added products; (2) enterprising farmers and farm groups became convinced of the agricultural potential of hemp in Canada, and obtained permits to conduct experimental cultivation; and (3) lobby groups convinced the government of Canada that narcotic forms of the hemp plant are distinct and distinguishable from fiber and oilseed forms. In March 1998, new regulations (under the Controlled Drugs and Substances Act) were provided to allow the commercial development of a hemp industry in Canada, and since then more than a thousand licenses have been issued. Hectares licensed for cultivation for 1998–2001 were respectively, 2,500, 14,200, 5,487, and 1,355, the decreasing trend due to a glut of seed produced in 1999 and pessimism over new potential regulations barring exports to the US. Information on the commercial potential of hemp in Canada is in Blade (1998), Marcus (1998), and Pinfold Consulting (1998). In the US, a substantial trade in hemp products has developed, based on imports of hemp fiber, grain, and oil. The American agricultural community has observed this, and has had success at the state level in persuading legislators of the advisability of experimental hemp cultivation as a means of evaluating the wisdom of re-establishing American hemp production. However, because of opposition by the federal government, to date there has only been a small experimental plot in Hawaii. Information on the commercial potential of hemp in the US is presented in the following.
CBD interacts with the body through the endogenous cannabinoid system (ECS) or endocannabinoid system. First discovered in the late 1980’s, the endocannabinoid system regulates the body’s homeostasis, or general state of balance, impacting such functions as mood, sleep, appetite, hormone regulation, and pain and immune response. Like an acrobat on a highwire, as the environment around us impacts our normal balance, the endocannabinoid system “corrects” by mediating our body’s reaction to keep us level.
Cannabis plants produce a unique family of terpeno-phenolic compounds called cannabinoids, some of which produce the "high" which may be experienced from consuming marijuana. There are 483 identifiable chemical constituents known to exist in the cannabis plant, and at least 85 different cannabinoids have been isolated from the plant. The two cannabinoids usually produced in greatest abundance are cannabidiol (CBD) and/or Δ9-tetrahydrocannabinol (THC), but only THC is psychoactive. Since the early 1970s, Cannabis plants have been categorized by their chemical phenotype or "chemotype", based on the overall amount of THC produced, and on the ratio of THC to CBD. Although overall cannabinoid production is influenced by environmental factors, the THC/CBD ratio is genetically determined and remains fixed throughout the life of a plant. Non-drug plants produce relatively low levels of THC and high levels of CBD, while drug plants produce high levels of THC and low levels of CBD. When plants of these two chemotypes cross-pollinate, the plants in the first filial (F1) generation have an intermediate chemotype and produce intermedite amounts of CBD and THC. Female plants of this chemotype may produce enough THC to be utilized for drug production.
Several animal studies have led researchers to believe that cannabis could reverse signs of aging in the brain. Aging mice treated with small daily doses of THC showed a reversal in cognitive decline. However, past studies on the effects of cannabis on human memory show less promising results. Still, with few viable treatments for dementia, medical marijuana is receiving increased attention in this area.
Jump up ^ Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, Egawa T, Kitamura Y, Uchida N, Nishimura R, Egashira N, Iwasaki K, Fujiwara M (January 2008). "Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism". Brain Research. 1188: 157–64. doi:10.1016/j.brainres.2007.09.090. PMID 18021759.
The Gateway Hypothesis states that cannabis use increases the probability of trying "harder" drugs. The hypothesis has been hotly debated as it is regarded by some as the primary rationale for the United States prohibition on cannabis use. A Pew Research Center poll found that political opposition to marijuana use was significantly associated with concerns about health effects and whether legalization would increase marijuana use by children.
In recent decades, the neurobiology of cannabinoids has been analyzed.[12-15] The first cannabinoid receptor, CB1, was identified in the brain in 1988. A second cannabinoid receptor, CB2, was identified in 1993. The highest expression of CB2 receptors is located on B lymphocytes and natural killer cells, suggesting a possible role in immunity. Endogenous cannabinoids (endocannabinoids) have been identified and appear to have a role in pain modulation, control of movement, feeding behavior, mood, bone growth, inflammation, neuroprotection, and memory.